July 26 Company Quick Takes: Lexicon hit by Phase III miss, scuttled deal; plus Xeljanz, Shield, Galapagos, Amarin and more

Sanofi canceling diabetes deal following Phase III misses

Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) dropped $2.79 (49%) to $2.90 in after-hours trading Friday after Sanofi (Euronext:SAN; NASDAQ:SNY) said it would terminate

Read the full 284 word article

User Sign In